Xeris Biopharma Holdings, Inc.
XERSNASDAQHealthcareDrug Manufacturers - Specialty & Generic
As of Oct 26, 2026 close
- Market cap
- $1.76B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $5.25$11.42
- Volume (live)
- -
- Avg. volume (3M)
- 3.07M
Xeris Biopharma Holdings (XERS) Stock Price & Financial Analysis
Xeris Biopharma Holdings Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $10.12 - $10.41 |
|---|---|
| 52-Week High | $11.42 |
| 52-Week Low | $5.25 |
| Open | $10.22 |
| Volume (last close) | 1.91M |
| Average Volume (3M) | 3.07M |
| Revenue (TTM) | 335.41M |
|---|---|
| Net Income (TTM) | -17.16M |
| Free Cash Flow (TTM) | 55.67M |
| EPS (TTM) | −$0.10 |
| Profit Margin | -5.12% |
| Operating Margin | 10.91% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 1.76B |
|---|---|
| Shares Outstanding | 172.82M |
| Price to Sales (P/S) | 5.26 |
| Price to Book (P/B) | -181.27 |
| EV/EBITDA | 84.03 |
| 50-Day MA | $8.99 |
|---|---|
| 200-Day MA | $7.38 |
| 1-Year Change | +18.95% |
Source: Market prices and company fundamentals. Data as of Oct 26, 2026. Data sources and methodology
Xeris Biopharma Holdings at a Glance
As of the Oct 26, 2026 close, Xeris Biopharma Holdings (XERS) has a market capitalization of $1.76B. The stock trades at 5.3× sales. Over the trailing twelve months it lost $17.16M on revenue of $335.41M and generated $55.67M of free cash flow. Revenue grew 36.3% year over year.
As of its latest reported balance sheet, it holds $121.75M in cash and securities against $252.59M of debt, a net debt position of $130.84M.
Xeris Biopharma Holdings does not currently pay a dividend.
The share price is up 18.9% over the past year. At $10.21 (the Oct 26, 2026 close) it sits within its 52-week range of $5.25 to $11.41, above its 200-day moving average of $7.38.
Based on 7 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $13.00, 27.3% above the Oct 26, 2026 close.
Frequently Asked Questions About Xeris Biopharma Holdings
What is the current stock price for XERS?
As of the Oct 26, 2026 close, XERS stock trades at $10.21. The 52-week range is $5.25–$11.42, with a day range of $10.12–$10.41.
What is the P/E ratio for XERS?
The P/E ratio (Price-to-Earnings) for XERS is shown in the Key Statistics section. This valuation metric helps compare Xeris Biopharma Holdings, Inc. to industry peers.
Does XERS pay dividends?
Xeris Biopharma Holdings does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for XERS?
Based on ratings from 7 professional analysts over the last 90 days, the consensus for XERS is Buy. The average 12-month price target is $13.00, a 27.3% upside from the Oct 26, 2026 close of $10.21.
What is the market cap of XERS?
As of the Oct 26, 2026 close, Xeris Biopharma Holdings's market capitalization is $1.76B, classifying it as a small-cap company. Xeris Biopharma Holdings operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.